Guozhu Zheng

This inventor holds 8 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignee: Stealth Biotherapeutics Inc.. Active years: 2022-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guozhu Zheng. Retrieved from https://idiyas.com/inventor/guozhu-zheng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 11)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 2 (Patent Applications = 10)

Average Co-Inventor Count = 2.8

ph-index = 1

Location History:

Lexington, MA (US) (2022 - 2024)
Needham, MA (US) (2024)

Company Filing History:

8 out of 69

Stealth Biotherapeutics Inc.

patents

Years Active: 2022-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12404300 - Mitochondria-targeting peptides (2025-09-02),

2. 12252554 - Analogs that target mitochondrial diseases (2025-03-18),

3. 12049455 - Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia (2024-07-30),

4. 12037350 - Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia (2024-07-16),

5. 12016843 - Compositions and methods for the treatment of amyotrophic lateral sclerosis, parkinson's disease, parkinson's disease with dementia, dementia with lewy bodies, and multiple system atrophy (2024-06-25),

6. 11795196 - Mitochondria-targeting peptides (2023-10-24),

7. 11584728 - Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia (2023-02-21),

8. 11273149 - Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy (2022-03-15),

Title: Guozhu Zheng: Innovator in Mitochondrial Therapeutics

Introduction

Guozhu Zheng is a prominent inventor based in Lexington, MA (US). He has made significant contributions to the field of mitochondrial therapeutics, holding a total of 8 patents. His work focuses on developing innovative compounds that target mitochondrial diseases and ischemia-reperfusion injuries.

Latest Patents

Among his latest patents are the mitochondria-targeting peptides, which include analogs of SBT-20. These compounds are designed to treat and prevent ischemia-reperfusion injury, particularly in cases of cardiac ischemia-reperfusion injury or myocardial infarction. Additionally, he has developed analogs that target mitochondrial diseases, specifically analogs of elamipretide (MTP-131), which also aim to address ischemia-reperfusion injuries.

Career Highlights

Guozhu Zheng has established himself as a key figure in the biotechnology sector. He is currently associated with Stealth Biotherapeutics Inc., where he continues to advance research in mitochondrial health and therapeutic applications. His innovative approach has garnered attention in the scientific community.

Collaborations

Throughout his career, Guozhu Zheng has collaborated with notable professionals in the field, including Dennis Keefe and Mark J Bamberger. These collaborations have further enhanced the impact of his research and innovations.

Conclusion

Guozhu Zheng's contributions to mitochondrial therapeutics exemplify the importance of innovation in addressing critical health challenges. His patents and ongoing research continue to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.